Venetoclax has demonstrated significant efficacy in inducing apoptosis in Bcl‐2‐dependent cancer cells, with a favorable safety profile compared with earlier, less specific Bcl‐2 inhibitors. The gene discussed is BCL2; the disease is cancer.